STOCK TITAN

Federated Hermes (NYSE: FHI) reports 5.94% stake in Ovid Therapeutics

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Federated Hermes, Inc. and related parties have filed a Schedule 13G reporting beneficial ownership of 7,737,166 shares of Ovid Therapeutics Inc. common stock, representing 5.94% of the class as of the 12/31/2025 event date. Federated Hermes and the Voting Shares Irrevocable Trust report sole voting and dispositive power over these shares, while individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue report shared voting and dispositive power over the same 7,737,166 shares.

The reporting persons state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ovid Therapeutics. Federated Hermes, the trust, and the individual filers expressly disclaim beneficial ownership of securities held by the managed funds referenced in the filing.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.


SCHEDULE 13G



Federated Hermes, Inc.
Signature:/s/J. Christopher Donahue
Name/Title:J. Christopher Donahue, as President of Federated Hermes, Inc.
Date:01/08/2026
Voting Shares Irrevocable Trust
Signature:/s/Thomas R. Donahue
Name/Title:Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:01/08/2026
Signature:/s/Ann C. Donahue
Name/Title:Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:01/08/2026
Signature:/s/J. Christopher Donahue
Name/Title:J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:01/08/2026
Thomas R. Donahue
Signature:/s/Thomas R. Donahue
Name/Title:Thomas R. Donahue
Date:01/08/2026
Ann C. Donahue
Signature:/s/Ann C. Donahue
Name/Title:Ann C. Donahue
Date:01/08/2026
J. Christopher Donahue
Signature:/s/J. Christopher Donahue
Name/Title:J. Christopher Donahue
Date:01/08/2026

Comments accompanying signature: SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY

FAQ

What ownership stake in Ovid Therapeutics Inc. does Federated Hermes (FHI) report?

The filing reports beneficial ownership of 7,737,166 shares of Ovid Therapeutics Inc. common stock, representing 5.94% of the outstanding class.

Who are the reporting persons in this Ovid Therapeutics Schedule 13G?

The reporting persons are Federated Hermes, Inc., the Voting Shares Irrevocable Trust, and individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue.

How much voting power over Ovid Therapeutics shares is reported in this filing?

Federated Hermes, Inc. and the Voting Shares Irrevocable Trust each report 7,737,166 shares with sole voting and dispositive power, while the three individual filers each report 7,737,166 shares with shared voting and dispositive power.

Is Federated Hermes seeking to influence control of Ovid Therapeutics with this stake?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of Ovid Therapeutics.

What does it mean that Federated Hermes and others disclaim beneficial ownership?

The filing states that Federated Hermes, the Voting Shares Irrevocable Trust, and the individual filers declare this report should not be construed as an admission that any of them is the beneficial owner of the securities held by the managed funds and they expressly disclaim beneficial ownership of such securities.

What is the date of the event triggering this Schedule 13G for Ovid Therapeutics?

The date of the event that required the filing of this Schedule 13G is listed as 12/31/2025.
Ovid Therapeutics Inc

NASDAQ:OVID

OVID Rankings

OVID Latest News

OVID Latest SEC Filings

OVID Stock Data

108.24M
117.40M
16.31%
34.69%
1.79%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK